Samsung Bioepis has announced positive results from a post-hoc and subgroup analysis of its recently EU-approved Byooviz (ranibizumab) biosimilar, at the same time as it disclosed the findings of a five-year follow-up study comparing the company’s Ontruzant (trastuzumab) biosimilar in early or locally advanced HER2 positive breast cancer with its reference brand, Herceptin.
From the first analysis, the Korean firm – which scooped an approval from the European Commission for Byooviz last month – said it had been able to demonstrate “important baseline factors that determine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?